<DOC>
	<DOCNO>NCT01606579</DOCNO>
	<brief_summary>PRI-724 new investigational drug study treat subject cancer advance myeloid malignancy . PRI-724 think work block Wnt signal pathway cancer cell need grow spread ( metastasize ) .</brief_summary>
	<brief_title>Safety Efficacy Study PRI-724 Subjects With Advanced Myeloid Malignancies</brief_title>
	<detailed_description>PRI-724 new investigational drug study treat subject cancer advance myeloid malignancy . PRI-724 think work block Wnt signal pathway cancer cell need grow spread ( metastasize ) . Purpose : - To test safety PRI-724 take intravenously ( vein ) . - To observe whether PRI-724 slow stop progression leukemia . - To find Maximum Tolerated Dose ( high safe dose ) first two part study . - To find dose PRI-724 use third part study possible future clinical trial study effectiveness additional safety . - To test safety combine PRI-724 approve cancer drug call dasatinib treat chronic myeloid leukemia ( CML ) . - To evaluate whether combination PRI-724 approve cancer drug dasatinib slow stops progression chronic myeloid leukemia ( CML ) . - To test safety combine PRI-724 approve cancer drug call Cytarabine treat acute myelogenous leukemia ( AML ) . - To evaluate whether combination PRI-724 approve cancer drug Cytarabine slow stop progression acute myelogenous leukemia ( AML ) . - To measure much PRI-724 appear remain blood infusion . - To measure several signal call biomarkers associate cancer blood see PRI-724 affect signal . Study Design : This single center , open-label escalating-dose cohort study 3 part : Part I MTD determine acute group patient ; Part II MTD determine non-acute group patient ; Part III safety tolerability escalate dos PRI-724 assess combination dasatinib CML patient low dose ara-C therapy AML patient ≥ 65 year age .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients 18 year old 2 . Part I : Patients one follow histologically cytologicallyproven condition : relapsed/refractory AML , relapsed/refractory MDS , advance CML AP BP ( i.e. , Acute Group patient ) . 3 . Part II : Patients one follow documented condition : CML CP Philadelphia chromosome ( Ph ) positive ( cytogenetics ) BCRABL1positive fluorescent situ hybridization [ FISH ] , PCR ) , well resistant least 2 FDAapproved tyrosine kinase inhibitor ( TKIs ) ; myeloproliferative neoplasia include : PMF myelofibrosis secondary polycythemia vera ( PV ) essential thrombocythemia ( ET ) myelofibrosis ( MF ) ( intermediate1 , intermediate2 high risk disease accord International Working Group [ IWG ] prognostic scoring system ) ( i.e. , NonAcute Group patient ) . 4 . Part III : Arm A : Patients AML 65 year age old refractory relapse disease , receive prior therapy eligible receive intensive frontline chemotherapy ( i.e. , Acute Group patient ) ; Arm B : Patients CML AP BP , either newly diagnose fail TKI therapy ( i.e. , Acute Group patient ) ; Arm C : Patients CML CP failure 2 FDAapproved TKIs ( i.e. , NonAcute group patient ) 5 . Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) scale 6 . Patients must prior therapy leukemia except hydroxyurea 1 week prior enter study recover toxic effect therapy 7 . Adequate organ function define : Serum creatinine ≤ 2.0 mg/dL calculate creatinine clearance ≥60 mL/min Total bilirubin ≤2 x ULN ( ≤5 x ULN consider due Gilbert 's syndrome hemolysis ) Alanine aminotransferase ( ALT ) ≤3xULN 8 . Patients must sign informed consent indicate aware investigational nature study . 9 . Women childbearing potential men practice effective method contraception . Women childbearing potential negative urine serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin within 7 day prior start PRI 724 . Exclusion Criteria 1 . Patients receive investigational agent 2 . Patients pregnant breastfeed 3 . Known hypersensitivity component PRI724 4 . Pretreatment QTcF interval &gt; 470 msec ( female ) &gt; 450 msec ( male ) 5 . Known active hepatitis B , hepatitis C 6 . Serious uncontrolled medical disorder active systemic infection current unstable decompensated medical condition , make undesirable unsafe patient participate study include : New York Heart Association ( NYHA ) Class 3 4 , myocardial infarction within 3 month , uncontrolled angina within 3 month , history clinically significant ventricular arrhythmia , diabetes mellitus ketoacidosis , chronic obstructive pulmonary disease ( COPD ) require hospitalization 6 month prior start treatment PRI724 . 7 . Any condition , include mental illness substance abuse deem Investigator likely interfere patient 's ability sign inform consent , cooperate , participate study 8 . Patients full dose anticoagulant dose warfarin ; patient prophylactic dose lowmolecular weight unfractionated heparin allow . 9 . Patients demonstrate intolerance dasatinib 100 mg daily eligible Part III/Arm B C study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>MDS</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>myeloproliferative neoplasia</keyword>
	<keyword>MPN</keyword>
</DOC>